Permanently discontinue if serious allergic reactions occur. Patients w/ AML, myelodysplastic syndrome, chronic myelogenous leukemia, secondary AML. De novo
AML in patients <55 yr w/ cytogenetics t(15; 17). High dose chemotherapy; do not use to increase cytotoxic chemotherapy dose beyond established dosage regimen. Potential higher risk in patients w/ recent history of pulmonary infiltrates or pneumonia. Preliminary signs of adult resp distress syndrome (ARDS); discontinue at the onset of pulmonary signs eg, cough, fever & dyspnea associated w/ radiological signs of pulmonary infiltrates & function deterioration w/ increased neutrophil count. Asymptomatic splenomegaly; splenic rupture; monitor spleen size & consider splenic rupture in patients w/ upper left abdominal or shoulder tip pain. Regularly monitor platelet count & hematocrit. Take special care in administering single or combination chemotherapeutic agents known to cause severe thrombocytopenia. Sickle cell crises; monitor appropriate clinical parameters & lab status, & be attentive to possible association to enlargement & vaso-occlusive crisis in patients w/ sickle cell disease. Discontinue immediately w/ leukocyte counts >50 x 109
/L after expected nadir. Blood progenitor cell mobilisation in patients or healthy donors. Needle cover contains natural dry rubber (latex derivative) which may cause allergic reactions. Increased bone marrow hematopoetic activity in response to growth factor therapy may cause transient positive bone imaging findings. Not for patients w/ rare hereditary problems of fructose intolerance. Pregnancy; do not use during lactation. Childn.